Related Experiment Video
Updated: Jun 27, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
A new approach to menopausal therapy: the tissue selective estrogen complex
1Women's Health and Musculoskeletal Biology Research, Discovery Liaison, Wyeth Research, Collegeville, Pennsylvania 01242, USA. kommb@wyeth.com
Reproductive Sciences (Thousand Oaks, Calif.)
|December 18, 2008
Summary
Tissue selective estrogen complexes offer a new menopausal therapy approach. This innovative treatment combines selective estrogen receptor modulators with estrogens for improved safety and tolerability.
Area of Science:
- Reproductive endocrinology and women's health.
- Pharmacology and drug development.
Background:
- Menopausal hormone therapy aims to alleviate symptoms and prevent bone loss.
- Current therapies may have limitations in safety and tolerability.
- Selective estrogen receptor modulators (SERMs) offer tissue-specific effects.
Purpose of the Study:
- Introduce the concept of tissue selective estrogen complexes (TSECs) for menopausal therapy.
- Provide the rationale for developing TSECs as a next-generation treatment.
- Explore the potential for improved therapeutic benefits and safety profiles.
Main Methods:
- Conceptual framework development.
- Review of existing estrogen and SERM pharmacology.
- Analysis of desired clinical outcomes for menopausal management.
Main Results:
- TSECs combine the actions of estrogens and SERMs.
- The clinical profile of a TSEC is determined by its components' tissue selectivity.
- Potential for enhanced efficacy and safety compared to monotherapy.
Conclusions:
- TSECs represent a novel approach to menopausal therapy.
- An ideal TSEC could offer comprehensive symptom relief and disease prevention.
- TSECs hold promise for improved tolerability and a favorable safety profile, including endometrial and vascular safety.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...